When Transparency Laws Have No Consequences
On March 30, 2026, the FDA sent messages to more than 2,200 medical product companies and researchers about clinical trials they'd registered but never reported results for, a reminder that they were violating a federal law now entering its nineteenth year of existence, according to an FDA announcement. The scale of the outreach reflects the scale of the problem: the agency's internal analysis found that 29.6% of studies subject to mandatory reporting requirements have no results information submitted to ClinicalTrials.gov, despite a legal obligation to post findings within one year of trial completion.
The reminder campaign, covering more than 3,000 registered trials, exposes a fundamental design flaw in how American medical research operates. The FDA Amendments Act of 2007 created clear requirements and authorized civil monetary penalties up to $15,107 per day for noncompliance, as specified in federal regulations. Yet nearly two decades later, the agency is asking for voluntary compliance, an implicit admission that the enforcement mechanism has failed.
The Incentive Architecture That Rewards Silence
The reporting requirement applies to interventional studies with a U.S. nexus involving FDA-regulated drugs, devices, or biologics, according to the FDA Amendments Act. Trial sponsors must submit results in tabular format one year after the primary completion date, including participant flow, demographic data, primary and secondary outcomes, statistical tests, and adverse event information. The law doesn't allow exemptions for unfavorable data or commercially sensitive findings.
Yet companies and researchers routinely fail to disclose negative trial results, creating what FDA Commissioner Marty Makary described as suppression of "unfavorable clinical trial results and keeping them secret from patients and the scientific community," according to the FDA statement. The commissioner framed the issue as a conflict between legal obligation and financial incentive: trial sponsors have "an ethical obligation to make results public regardless of the data's influence on the company's share price."
That tension, between transparency requirements and stock price protection, explains the 30% noncompliance rate better than any theory about administrative burden or technical confusion. Publication bias doesn't happen by accident. When negative results disappear while positive results get published, the medical literature systematically overrepresents successes and underrepresents failures. Doctors prescribing treatments, patients choosing between options, and researchers designing new trials all work from an incomplete and distorted evidence base.
The FDA's enforcement ladder theoretically escalates from Pre-Notices of Noncompliance to Notices of Noncompliance to civil monetary penalties exceeding $10,000 per day, as outlined in agency guidance documents. The agency retains authority to seek criminal and civil action and to recommend withholding government grant funding. But the March 30 messages, described by the FDA as "an extra step to provide responsible parties opportunity to comply voluntarily before further regulatory action", suggest that ladder rarely gets climbed.
How Missing Data Reaches Patients
The path from unreported trial to patient harm follows a predictable sequence. When a pharmaceutical company completes a trial showing a drug causes unexpected liver damage in 8% of participants, that adverse event data should appear on ClinicalTrials.gov within one year. Instead, if the company doesn't report, the information enters a regulatory void. The FDA may send a Pre-Notice of Noncompliance, a warning with no penalty. If the company still doesn't comply, the agency may send a Notice of Noncompliance, another warning. The civil monetary penalties authorized by law remain largely theoretical; the FDA has issued few such penalties despite thousands of violations.
Meanwhile, doctors prescribing that drug see only the published positive trials. A physician treating a patient with existing liver issues searches the medical literature and finds three published studies showing the drug works, with adverse event rates that look manageable. The unpublished trial showing 8% liver damage never enters her decision calculus. She prescribes the drug. Her patient, who consented based on incomplete safety information, faces a risk neither of them knew existed. This isn't a hypothetical chain, it's how publication bias translates directly into clinical decisions made with systematically distorted information.
When Public Funding Produces Private Secrets
The noncompliance extends beyond pharmaceutical companies protecting commercial interests. Some publicly funded clinical trials appear among those that haven't submitted required results information to ClinicalTrials.gov, according to the FDA's analysis. Taxpayers fund the research, federal law mandates transparency, and the results still vanish into institutional filing cabinets.
Tracy Beth Hoeg, Acting Director of the Center for Drug Evaluation and Research, expressed support for the initiative to increase prompt publication of results information, according to the FDA statement. The statement reflects internal FDA alignment on the problem. But if everyone from the commissioner to center directors agrees that trial results must be public, the question becomes: why does agreement require 2,200 reminder emails?
The answer lies in comparing American enforcement to European action. In October 2023, the European Medicines Agency eliminated the deferral mechanism that had allowed sponsors to delay certain data and document publication for up to seven years after trial end, according to EMA policy updates. The EMA closed the loophole. The FDA, facing the same publication bias problem, sent polite messages asking for voluntary compliance with a law old enough to vote.
The Knowledge Commons Built on Missing Data
Nondisclosure creates significant gaps in the public record that compound across the entire drug development ecosystem. When a trial shows a treatment doesn't work or causes unexpected harm, that negative result should inform every subsequent decision, by doctors considering prescriptions, patients weighing options, researchers designing follow-up studies, and regulators evaluating new applications. Publication bias doesn't just hide individual failures; it creates a distorted perception of the safety and efficacy of entire classes of medical products.
A cancer patient choosing between two treatments sees published trials showing both work. What she doesn't see: the three unpublished trials showing one treatment failed, or the adverse event data that never made it to ClinicalTrials.gov. Her informed consent is manufactured from incomplete information, and the incompleteness isn't random, it's systematically biased toward making treatments look safer and more effective than the full evidence supports.
The same dynamic affects medical knowledge at every level. Meta-analyses that synthesize trial results to guide clinical practice can only analyze the trials they can find. Systematic reviews that inform treatment guidelines work from a literature that overrepresents success. The evidence-based medicine framework assumes the evidence base is complete, or at least that missing data is random rather than strategically suppressed.
Voluntary Compliance as Policy Failure
The FDA's request for voluntary compliance with federal law requirements carries an unintended message: the mandatory reporting system isn't actually mandatory in any meaningful sense. Companies and researchers have learned through nearly two decades of experience that noncompliance carries no practical consequences. The agency can issue Pre-Notices and Notices, can calculate daily penalty amounts, can describe its escalation authority, but if 2,200 entities ignore the requirements simultaneously, the enforcement threat loses credibility.
The March 30 messages represent an attempt to achieve through persuasion what the law was supposed to achieve through obligation. Whether that approach will move the 29.6% noncompliance rate remains unclear. What's already clear is that a transparency law without enforcement produces the appearance of accountability while allowing the underlying behavior, suppressing unfavorable results, to continue largely unchanged.
Medical research in the United States operates on an honor system that dishonors patients. The law requires transparency. The incentives reward opacity. And the enforcement mechanism, after 19 years, still relies on asking nicely.
Every hidden trial result is a hole in medical knowledge that patients fall through when making decisions about their care. The FDA knows where 3,000 of those holes are. It sent 2,200 reminders. Now the question is whether reminder emails can fix a system designed to fail.